文献

PA005171：重组小鼠IgG2c同型对照抗体，体内实验级（In Vivo Grade Recombinant Mouse IgG2c Isotype Control Antibody）

小鼠 IgG2c 抗体由部分近交系小鼠品系（如 C57BL/6、C57BL/10、SJL 以及 NOD 小鼠）产生，这类小鼠不表达小鼠 IgG2a 抗体，反之亦然。如果科研动物实验使用上述小鼠品系，优先选用 IgG2c 抗体，而非 IgG2a 抗体。经过 Fc 工程改造的 IgG 抗体类型日益增多，其中 Fc 沉默、Fc 效应功能失活的抗体应用最为广泛。因此，该类实验场景应当选用野生型小鼠 IgG2c 同型对照以及 Fc 沉默型小鼠 IgG2c 同型对照突变体。

小鼠IgG2c同型对照抗体部分参考文献：

1.Lymphatic pumping technique in mice alters blood parameters and metastatic melanoma in an age-dependent manner

Kopchick, J. J., et al. Exp Biol Med (Maywood). 2026 Mar 30;251:10850. PMID: 41982211; PMCID: PMC13071501

“The experimental design of the four in vivo experiments reported in this study is shown in … In addition to the sham and LPT treatments, the mice were treated with anti-mouse programmed cell death protein 1 (PD1) antibody (#PA007163.m2cLA, Syd Labs) or an isotype control antibody (#PA007141, Syd Labs). Four treatments of 200 μg of antibody diluted in 100 μL of PBS (2 mg/mL) were administered intraperitoneally between days 9 and 21 of the experiment. The anti-PD1 dosing regimen of 200 ug per injection was selected based on established murine immunotherapy protocols rather than allometric scaling from human doses, consistent with prior studies demonstrating biological efficacy at this dose [21, 22]. Mice were divided into four treatment groups: group 1 received sham treatment and isotype control antibodies; group 2 received LPT and isotype control antibodies; group 3 received sham treatment and anti-PD1 antibodies; and group 4 received LPT treatment and anti-PD1 antibodies. The cancer cells were injected on experimental day 0, treatments started on day 8, ended on day 22, and the mice were euthanized with carbon dioxide inhalation and on day 25.”